Physician profile
Hany Samir Abd-El Malek
NPI 1457397978
$18,894.03
in general payments reported to CMS, 2019-2025
39 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 90% of Critical Care Medicine (Anesthesiology) providers received nationally (typical 2025 total: $97.90).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,901 · 2020: $2,135 · 2021: $5,027 · 2022: $3,677 · 2023: $1,058 · 2024: $833 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,154.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $4,393.90 | 2019-2025 | Impella |
| Livanova USA, INC. | $4,010.38 | 2019-2024 | Lifesparc, Protekduo |
| Haemonetics Corporation | $2,000.00 | 2021 | |
| La Jolla Pharmaceutical Company | $1,131.22 | 2020-2025 | Giapreza, Zevtera |
| Abbvie INC. | $903.93 | 2019-2025 | Mavyret, Teflaro |
| Abbott Laboratories | $623.69 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Fisher & Paykel Healthcare INC | $528.88 | 2023-2024 | Fisher & Paykel Healthcare |
| Alexion Pharmaceuticals, INC. | $521.42 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $513.39 | 2019-2025 | Wainua |
| Actelion Pharmaceuticals US, INC. | $398.17 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.49 | 2019 | |
| Shionogi INC | $255.37 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $241.26 | 2019 | |
| Rigel Pharmaceuticals, INC. | $215.26 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.80 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hany Abd-El Malek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.